Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Weight Gain in ART

Listen as Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy.
Joseph J. Eron, Jr., MD
Released: August 30, 2021

In this episode, Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy.

Listen as he gives his perspectives on:

  • Weight gain following ART initiation by ARV class and ARV drug
  • Results of the ADVANCE and GEMINI-1 and -2 studies, with exploration of weight, risk of CVD and diabetes
  • BMI changes in PWH
  • DHHS and IAS-USA guidelines for initial therapy

Information on this Educational Activity

Faculty

Joseph J. Eron, Jr., MD

Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, Trio Health, and ViiV and funds for research support from Gilead Sciences, Janssen, and ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

From Clinical Care Options (CCO): podcast by Drs Rageshri Dhairyawan and Solange L. Baptiste on barriers to HIV care engagement in BIPOC populations globally

person default Solange L. Baptiste, ScM Rageshri Dhairyawan, MBBS, BSc, FCRP, DipGUM, DipHIV, DFSRH Released: January 26, 2022

Slides from Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 26, 2022

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings